Immunology of canine leishmaniasis

Parasite Immunology

Volumn 28, Issue 7, 2006, Pages 329-337

  Barbieri C L ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Canine leishmaniasis; Immune response; Leishmania (L.) chagasi; Leishmania (L.) infantum; Vaccine

Indexed keywords

ADJUPRIME; BCG VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; CHIMERIC PROTEIN; CYSTEINE PROTEINASE; CYTOKINE; FUCOSE MANNOSE LIGAND; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; MPL SE; MURAMYL DIPEPTIDE; PARASITE ANTIGEN; PLASMID DNA; PROTEIN LACK; PROTEIN LEIF; PROTEIN LIESAP; PROTEIN LIF2; PROTEIN LMSTI1; PROTEIN MML; PROTEIN TSA; RECOMBINANT ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DOG; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; NONHUMAN; PARASITE CONTROL; PARASITE IMMUNITY; PARASITE PREVALENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; TH1 CELL; TH2 CELL; VISCERAL LEISHMANIASIS;

ANIMALS; DOG DISEASES; DOGS; LEISHMANIASIS, VISCERAL; PROTOZOAN VACCINES; TH1 CELLS; TH2 CELLS;

ANIMALIA; CANIS FAMILIARIS;

EID: 33745676566     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2006.00840.x     Document Type: Review

References (64)

1. Rioux JA, Lanotte G, Serres E, Pratlong F, Bastien P & Perières J. Taxonomy of Leishmania. Use of isoenzymes. Suggestions for a new classification. Ann Parasitol Hum Comp 1990; 65: 111-125.
2. Mauricio IL, Stothard JR & Miles MA. The strange case of Leishmania chagasi. Parasitol Today 2000; 16: 188-189.
3. World Health Organization. Leishmaniasis. Fourteenth Programme Report. UNDP/World Bank/Special Programme for Research and Training in Tropical Diseases (TDR). Tropical Disease Research Progress 1997-1998. Geneva: World Health Organization; 1999: 1-6.
4. Arias JR, Monteiro PS & Zicker F. The reemergence of visceral leishmaniasis in Brazil. Emerg Infec Dis 1996; 2: 145-146.
5. Ashford DA, David JR, Freire M et al. Studies on control of visceral leishmaniasis: impact of dog control on canine and human visceral leishmaniasis in Jacobina, Bahia, Brazil. Am J Trop Med Hyg 1998; 59: 53-57.
6. Ciaramella P, Oliva G, Luna RD et al. A retrospective clinical study of canine leishmaniasis in 150 dogs naturally infected by Leishmania infantum. Vet Rec 1997; 141: 539-543.
7. Cardoso L, Neto F, Sousa JC, Rodrigues M & Cabral M. Use of a leishmanin test in the detection of canine Leishmania-specific cellular immunity. Vet Parasitol 1998; 79: 213-220.
8. Pinelli E, Killick-Kendrick R, Wagenaar J, Bernardina W, Del Real G & Ruitenberg J. Cellular and humoral responses in dogs experimentally and naturally infected with Leishmania infantum. Infect Immun 1994; 62: 229-235.
9. Solano-Gallego L, Llull J, Ramos G et al. The Ibizian hound presents a predominantly cellular immune response against natural Leishmania infection. Vet Parasitol 2000; 90: 37-45.
10. De Luna R, Vuotto ML, Ielpo MTL et al. Early suppression of lymphoproliferative response in dogs with natural infection by Leishmania infantum. Vet Immunol Immunopathol 1999; 70: 95-103.
11. Martínez-Moreno A, Moreno T, Martínez-Moreno FJ, Acosta I & Hernández S. Humoral and cell-mediated immunity in natural and experimental canine leishmaniasis. Vet Immunol Immunopathol 1995; 48: 209-220.
12. Pinelli E, Gonzalo RM, Boog CJP et al. Leishmania infantum-specific T cell lines derived from asymptomatic dogs that lyse infected macrophages in a major histocompatibility complex-restricted manner. Eur J Immunol 1995; 25: 1594-1600.
13. Pinelli E, van der Kaaij SY, Slappendel R et al. Detection of canine cytokine gene expression by reverse transcription-polymerase chain reaction. Vet Immunol Immunopathol 1999; 69: 121-126.
14. Santos-Gomes GM, Rosa R, Leandro C, Cortes S, Romão P & Silveira H. Cytokine expression during the outcome of canine experimental infection by Leishmania infantum. Vet Immunol Immunopathol 2002; 88: 21-30.
15. Abranches P, Santos-Gomes G, Rachamim N, Campino L, Schnur LF & Jaffe CL. An experimental model for canine leishmaniasis. Parasite Immunol 1991; 13: 537-550.
16. Vouldoukis I, Drapier JC, Nüssler AK et al. Canine visceral leishmaniasis: successful chemotherapy induces macrophage antileishmanial activity via the L-arginine nitric oxide pathway. Antimicrob Agents Chemother 1996; 40: 253-256.
17. Pinelli E, Gebhard D, Mommaas AM et al. Infection of a canine macrophage cell line with Leishmania infantum: determination of nitric oxide production and anti-leishmanial activity. Vet Parasitol 2000; 92: 181-189.
18. Panaro MA, Acquafredda A, Lisi S et al. Nitric oxide production by macrophages of dogs vaccinated with killed Leishmania infantum promastigotes. Comp Immunol Microbiol Infect Dis 2001; 24: 187-195.
19. Strauss-Ayali D, Baneth G, Shor S, Okano F & Jaffe CL. Interleukin-12 augments a Th1-type immune response manifested as lymphocyte proliferation and interferon gamma production in Leishmania infantum-infected dogs. Int J Parasitol 2005; 35: 63-73.
20. Ramiro MJ, Zárate JJ, Hanke T et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 2003; 21: 2474-2484.
21. Chamizo C, Moreno J & Alvar J. Semi-quantitative analysis of cytokine expression in asymptomatic canine leishmaniasis. Vet Immunol Immunopathol 2005; 103: 67-75.
22. Quinnell RJ, Courtenay O, Shaw MA et al. Tissue cytokine responses in canine visceral leishmaniasis. J Infect Dis 2001; 183: 1421-1424.
23. Ghalib HW, Piuvezam MR, Sheiky YA et al. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 1993; 92: 324-329.
24. Pinheiro PHC, Dias SS, Eulálio KD, Mendonça IL, Katz S & Barbiéri CL. Recombinant cysteine proteinase from Leishmania (Leishmania) chagasi implicated in human and dog T-cell responses. Infect Immun 2005; 73: 3787-3789.
25. Rafati S, Nakhaee A, Taheri T et al. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 2005; 23: 3716-3725.
26. Deplazes P, Smith NC, Arnold P, Lutz H & Eckert J. Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites. Parasite Immunol 1995; 17: 451-458.
27. Nieto CG, Garcia-Alonso M, Requena JM, et al. Analysis of the humoral immune response against total and recombinant antigens of Leishmania infantum: correlation with disease progression in canine experimental leishmaniasis. Vet Immunol Immunopathol 1999; 67: 117-130.
28. Bourdoiseau G, Bonnefont C, Hoareau E, Boehringer C, Stolle T & Chabanne L. Specific IgG1 and IgG2 antibody and lymphocyte subset levels in naturally Leishmania infantum-infected treated and untreated dogs. Vet Immunol Immunopathol 1997; 59: 21-30.
29. Leandro C, Santos-Gomes GM, Campino L et al. Cell mediated immunity and specific IgG1 and IgG2 antibody response in natural and experimental canine leishmaniosis. Vet Immunol Immunopathol 2001; 79: 273-284.
30. Quinnell RJ, Courtenay O, Garcez LM et al. IgG subclass responses in a longitudinal study of canine visceral leishmaniasis. Vet Immunol Immunopathol 2003; 91: 161-168.
31. Almeida MAO, Jesus EEV, Sousa-Atta MLB, Alves LC, Berne MEA & Atta AM. Antileishmanial antibody profile in dogs naturally infected with Leishmania chagasi. Vet Immunol Immunopathol 2005; 106: 151-158.
32. Iniesta L, Gállego M & Portús M. Immunoglobulin G and E responses in various stages of canine leishmaniosis. Vet Immunol Immunopathol 2005; 103: 77-81.
33. Kirman JR & Seder RA. DNA vaccination: the answer to stable, protective T-cell memory? Curr Opin Immunol 2003; 15: 471-476.
34. Altet L, Francino O, Solano-Gallego L, Renier C & Sánchez A. Mapping and sequencing of the canine NRAMP1 gene and identification of mutations in leishmaniasis-susceptible dogs. Infect Immun 2002; 70: 2763-2771.
35. Quinnell RJ, Kennedy LJ, Barnes A et al. Susceptibility to visceral leishmaniasis in the domestic dog is associated with MHC class II polymorphism. Immunogenetics 2003; 55: 23-28.
36. Stobie L, Gurunathan S, Prussin C et al. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. Proc Natl Acad Sci USA 2000; 97: 8427-8432.
37. Lasri S, Sahibi H, Sadak A, Jaffe CL & Rhalem A. Immune responses in vaccinated dogs with autoclaved Leishmania major promastigotes. Vet Res 1999; 30: 441-449.
38. Mayrink W, Genaro O, França-Silva JC et al. Phase I and II open clinical trials of a vaccine against Leishmania chagasi infections in dogs. Mem Inst Oswaldo Cruz 1996; 91: 695-697.
39. Genaro O, Pinto JA, Costa CA et al. Phase III randomized double blind clinical trial on the efficacy of a vaccine against canine visceral leishmaniasis in urban area of Montes Claros, MG. Brazil. Mem Inst Oswaldo Cruz 1996; 91: 166.
40. Mohebali M, Fallah E, Jamshidi S & Hajjaran H. Vaccine trial against canine visceral leishmaniasis in the Islamic Republic of Iran. East Med Health J 1998; 4: 234-238.
41. Fallah E, Mohebali M & Zareh NM. Preparation and evaluation of Leishmania vaccines in Iran for the control of kala-azar. Acta Parasitol 2000; 45: 202-203.
42. Mohebali M, Khamesipour A, Mobedi I, Zarei Z & Hashemi-Fesharki R. Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran. Vaccine 2004; 22: 4097-4100.
43. Ogunkolade BW, Vouldoukis I, Frommel D, Davoust B, Rhodes-Feuillete A & Monjour L. Immunization of dogs with a Leishmania infantum-derived vaccine. Vet Parasitol 1988; 28: 33-41.
44. Dunan S, Frommel D, Monjour L, Ogunkolade BW, Cruz A & Quilici M. Vaccination trial against canine visceral leishmaniasis. Parasite Immunol 1989; 11: 397-402.
45. da Silva VO, Borja-Cabrera GP, Pontes NNC et al. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN). Vaccine 2001; 19: 1082-1092.
46. Borja-Cabrera GP, Correia Pontes NN, da Silva VO et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic área of Brazil (São Gonçalo do Amaranto, RN). Vaccine 2002; 20: 3277-3284.
47. Mendes CO, Paraguai de Souza E, Borja-Cabrera GP et al. IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniosis. Vaccine 2003; 21: 2589-2597.
48. Borja-Cabrera GP, Mendes AC, Paraguai de Souza E et al. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 2004; 22: 2234-2243.
49. Nogueira FS, Moreira MAB, Borja-Cabrera GP et al. Leishmune® vaccine blocks the transmission of canine visceral leishmaniasis. Absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs. Vaccine 2005; 23: 4805-4810.
50. Lemesre JL, Holzmuller P, Cavaleyra M, Gonçalves RB, Hottin G & Papierok G. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 2005; 23: 2825-2840.
51. Gonçalves da Costa S, Santos EB & Lagrange PH. Vaccination of mice against Leishmania mexicana amazonensis with microsomal fraction associated with BCG. Ann Inst Pasteur Immunol 1988; 139: 143-156.
52. Soto M, Requena JM, Quijada L & Alonso C. Multicomponent chimeric antigen for serodiagnosis of canine visceral leishmaniasis. J Clin Microbiol 1998; 36: 58-63.
53. Molano I, García Alonso M, Mirón C et al. A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet Immunol Immunopathol 2003; 92: 1-13.
54. Fujiwara RT, Vale AM, França da Silva JC et al. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis. Vet Res 2005; 36: 827-838.
55. Gradoni L, Manzillo VF, Pagano A et al. Failure of a multisubunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vaccine 2005; 23: 5245-5251.
56. Dias SS, Pinheiro PHC, Katz S, Santos MRM & Barbiéri CL. A recombinant cysteine proteinase from Leishmania (Leishmania) chagasi suitable for serodiagnosis of American visceral leishmaniasis. Am J Trop Med Hyg 2005; 72: 126-132.
57. Rafati S, Nakhaee A, Taheri T et al. Expression of cysteine proteinase type I and II of Leishmania infantum and their recognition by sera during canine and human visceral leishmaniasis. Exp Parasitol 2003; 103: 143-151.
58. Nakhaee A, Taheri T, Taghikhani M et al. Humoral and cellular immune responses against Type I cysteine proteinase of Leishmania infantum are higher in asymptomatic than symptomatic dogs selected from a naturally infected population. Vet Parasitol 2004; 119: 107-123.
59. Pinheiro PHC. Immunization of dogs with a recombinant cysteine proteinase from Leishmania (Leishmania) chagasi (rLdccys1) in an endemic area of visceral leishmaniasis, Teresina/PI. PhD thesis. 2005. São Paulo: Department of Microbiology, Immunology and Parasitology. Universidade Federal de São Paulo - Escola Paulista de Medicina.
60. Molina R, Amela C, Nieto J et al. Infectivity of dogs naturally infected with Leishmania infantum to colonized Phlebotomus perniciosus. Trans R Soc Trop Med Hyg 1994: 88: 491-493.
61. Mary C, Faraut F, Lascombe L & Dumon H. Quantification of Leishmania infantum DNA by a real-time PCR assay with high sensitivity. J Clin Microbiol 2004; 42: 5249-5255.
62. Rolão N, Cortes S, Rodrigues OR & Campino L. Quantification of Leishmania infantum parasites in tissue biopsies by real-time polymerase chain reaction and polymerase chain reaction-enzyme-linked immunosorbent assay. J Parasitol 2004; 90: 1150-1154.
63. Gradoni L. An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine. Vet Parasitol 2001; 100: 87-103.
64. Harrus S, Waner T, Friedmann-Morvinski D, Fishman Z, Bark H & Harmelin A. Down-regulation of MHC class II receptors of DH82 cells, following infection with Ehrlichia canis. Vet Immunol Immunopathol 2003; 96: 239-243.